Pfizer Inc. (PFE)
28.45
-0.36
(-1.25%)
USD |
NYSE |
Sep 04, 16:00
28.42
-0.03
(-0.11%)
Pre-Market: 20:00
Pfizer Research and Development Expense (Quarterly) : 2.746B for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.746B |
| March 31, 2026 | 2.452B |
| December 31, 2025 | 3.133B |
| September 30, 2025 | 2.492B |
| June 30, 2025 | 2.443B |
| March 31, 2025 | 2.179B |
| December 31, 2024 | 3.017B |
| September 30, 2024 | 2.565B |
| June 30, 2024 | 2.676B |
| March 31, 2024 | 2.48B |
| December 31, 2023 | 2.773B |
| September 30, 2023 | 2.682B |
| June 30, 2023 | 2.629B |
| March 31, 2023 | 2.494B |
| December 31, 2022 | 3.615B |
| September 30, 2022 | 2.696B |
| June 30, 2022 | 2.815B |
| March 31, 2022 | 2.301B |
| December 31, 2021 | 5.915B |
| September 30, 2021 | 2.681B |
| June 30, 2021 | 2.239B |
| March 31, 2021 | 1.994B |
| December 31, 2020 | 3.352B |
| September 30, 2020 | 2.299B |
| June 30, 2020 | 2.075B |
| Date | Value |
|---|---|
| March 31, 2020 | 1.677B |
| December 31, 2019 | 2.814B |
| September 30, 2019 | 2.28B |
| June 30, 2019 | 1.831B |
| March 31, 2019 | 1.696B |
| December 31, 2018 | 2.44B |
| September 30, 2018 | 1.999B |
| June 30, 2018 | 1.79B |
| March 31, 2018 | 1.737B |
| December 31, 2017 | 2.304B |
| September 30, 2017 | 1.85B |
| June 30, 2017 | 1.776B |
| March 31, 2017 | 1.701B |
| December 31, 2016 | 2.502B |
| September 30, 2016 | 1.872B |
| June 30, 2016 | 1.742B |
| March 31, 2016 | 1.721B |
| December 31, 2015 | 2.345B |
| September 30, 2015 | 1.719B |
| June 30, 2015 | 1.73B |
| March 31, 2015 | 1.876B |
| December 31, 2014 | 3.196B |
| September 30, 2014 | 1.789B |
| June 30, 2014 | 1.714B |
| March 31, 2014 | 1.612B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Johnson & Johnson | 3.603B |
| Eli Lilly & Co. | 3.819B |
| Merck & Co., Inc. | 9.229B |
| Bristol Myers Squibb Co. | 2.316B |
| Viatris, Inc. | 245.20M |